Tissue concentrations of platelet-activating factor in colorectal carcinoma: inverse relationships with Dukes' stage of patients Yves Denizot*,1, Alain Gainant2, Laurence Guglielmi1, Stephane Bouvier2, Pierre Cubertafond2 and Murielle Mathonnet2 1UMR CNRS 6101, Laboratoire d'Immunologie, Faculte de Medecine, 2 rue Dr Marcland, Limoges 87025, France; 2Service de Chirurgie Digestive, Endocrinienne et Generale, 2 avenue M Luther King, Limoges 87042, France The lipid mediator platelet-activating factor (PAF) plays a role in cancer. We investigated its presence in human colon carcinoma by assessing the levels of tissue phospholipase A2 (PLA2, the key enzyme in the genera- tion of the lyso-PAF precursor), lyso-PAF, PAF and acetylhydrolase activity (AHA, the key enzyme in PAF degradation) in colorectal cancer patients and by correlat- ing them with Dukes' classification. The results high- lighted that the tumour tissues of Dukes' A and B patients had significantly higher PLA2, lyso-PAF, PAF and AHA levels as compared with nontumour tissues. Dukes' C patients had higher PLA2, lyso-PAF and AHA levels but unchanged PAF. Dukes' D patients had higher AHA levels but unchanged PLA2, lyso-PAF and PAF. A pathophysiological role for PAF is suggested in human colon carcinoma. Oncogene (2003) 22, 7222–7224. doi:10.1038/sj.
- hypothesis human
- carcinoma cell
- colon carcinoma
- human colon
- colorectal carcinoma
- lyso
- tumour tissue
- since paf
- paf precursor